| For: | Pattullo V. Hepatitis B reactivation in the setting of chemotherapy and immunosuppression - prevention is better than cure. World J Hepatol 2015; 7(7): 954-967 [PMID: 25954478 DOI: 10.4254/wjh.v7.i7.954] |
|---|---|
| URL: | https://www.wjgnet.com/1007-9327/full/v7/i7/954.htm |
| Number | Citing Articles |
| 1 |
Maria Guarino, Marco Picardi, Anna Vitiello, Novella Pugliese, Matilde Rea, Valentina Cossiga, Fabrizio Pane, Nicola Caporaso, Filomena Morisco. Viral Outcome in Patients with Occult HBV Infection or HCV-Ab Positivity Treated for Lymphoma. Annals of Hepatology 2017; 16(2) doi: 10.5604/16652681.1231579
|
| 2 |
Marcela V. Maus, Michail S. Lionakis. Infections associated with the new ‘nibs and mabs’ and cellular therapies. Current Opinion in Infectious Diseases 2020; 33(4) doi: 10.1097/QCO.0000000000000656
|
| 3 |
Rick-Léonid Ngoua Meye Misso, Cédric Sima Obiang, Joefred Mbogho Abogo, Jean Calvin Nguele, Grace Winnis Bissesang-Bi-Obame, Darril Gueluna Layita, Joseph Privat Ondo, Louis-Clément Obame Engonga. Biochemical profile of HIV and HBV coinfected patients: a cross-sectional study, in Libreville, Gabon. Discover Medicine 2026; 3(1) doi: 10.1007/s44337-026-00684-8
|
| 4 |
Xiaoyang Li, Yu Zheng, Hongming Zhu, Xiaojing Lin, Yunxiang Zhang, Yubing Zhao, Jiong Hu, Junmin Li. Risk of Onset of Hematological Malignancies in Patients Infected with the Hepatitis B Virus: Results from a Large-Scale Retrospective Cohort Study in China. Acta Haematologica 2017; 137(4) doi: 10.1159/000468973
|
| 5 |
Bilal Toka, Ahmet Tarik Eminler, Emel Gönüllü, Mukaddes Tozlu, Mustafa Ihsan Uslan, Erkan Parlak, Oğuz Karabay, Aydin Seref Koksal. Rheumatologists’ awareness of hepatitis B reactivation before immunosuppressive therapy. Rheumatology International 2019; 39(12) doi: 10.1007/s00296-019-04437-y
|
| 6 |
Malowane H. Ngoato, Edina Amponsah-Dacosta, Ntombifuthi Blose, Selokela G. Selabe, Thembeni L. Msibi, Mojakgomo H. Motswaledi, Andrew M. Musyoki. Hepatitis B virus infection in patients presenting for immunosuppressive cancer therapy with and without underlying HIV infection. Frontiers in Virology 2023; 3 doi: 10.3389/fviro.2023.1160078
|
| 7 |
Hasmukh Jain, Neha Sharma, Devanshee Shah, Thomas Eipe, Netra Ghandade, Jayashree Thorat, Bhausaheb Bagal, Lingaraj Nayak, Alok Shetty, Anupa John, Sanjay K. Biswas, Gaurav Salunkhe, Sridhar Sundaram, Prachi S. Patil, Manju Sengar. Risk of Hepatitis B Reactivation Among ALL Patients With Occult Hepatitis B Infection. JCO Global Oncology 2026; 12(1) doi: 10.1200/GO-25-00262
|
| 8 |
Charat Thongprayoon, Wisit Kaewput, Konika Sharma, Karn Wijarnpreecha, Napat Leeaphorn, Patompong Ungprasert, Ankit Sakhuja, Franco H Cabeza Rivera, Wisit Cheungpasitporn. Outcomes of kidney transplantation in patients with hepatitis B virus infection: A systematic review and meta-analysis. World Journal of Hepatology 2018; 10(2): 337-346 doi: 10.4254/wjh.v10.i2.337
|
| 9 |
Apostolos Koffas, Upkar Gill, Patrick Kennedy. Evidence‐based Gastroenterology and Hepatology 4e. 2019; doi: 10.1002/9781119211419.ch33
|
| 10 |
G. I. Gridneva, B. S. Belov, E. S. Aronova. Chronic viral hepatitis B and rheumatic diseases: Modern view on problem. Medical alphabet 2022; (29) doi: 10.33667/2078-5631-2022-29-20-28
|
| 11 |
Marco Fiore, Sebastiano Leone, Alberto Enrico Maraolo, Emilio Berti, Giovanni Damiani. Liver Illness and Psoriatic Patients. BioMed Research International 2018; 2018 doi: 10.1155/2018/3140983
|
| 12 |
Francis Mugeni Wanyama, Rudolf Tauber, Alfred Mokomba, Catherine Nyongesa, Véronique Blanchard. The Burden of Hepatitis B, Hepatitis C, and Human Immunodeficiency Viruses in Ovarian Cancer Patients in Nairobi, Kenya. Infectious Disease Reports 2022; 14(3) doi: 10.3390/idr14030047
|
| 13 |
Mitchell L. Shiffman. Management of Acute Hepatitis B Virus Infection. Current Hepatology Reports 2020; 19(3) doi: 10.1007/s11901-020-00536-8
|
| 14 |
Chih-An Shih, Wen-Chi Chen. Prevention of hepatitis B reactivation in patients requiring chemotherapy and immunosuppressive therapy. World Journal of Clinical Cases 2021; 9(21): 5769-5781 doi: 10.12998/wjcc.v9.i21.5769
|
| 15 |
Betül ERSÖZ ACAR. İmmünsüpresif ilaçlar ve HBV reaktivasyonu. Bolu Abant Izzet Baysal Universitesi Tip Fakultesi Abant Tip Dergisi 2022; doi: 10.47493/abantmedj.1051982
|
| 16 |
Riha Vaidya, Joseph M. Unger, Rohit Loomba, Jessica P. Hwang, Rashmi Chugh, Monica A. Tincopa, Kathryn B. Arnold, Dawn L. Hershman, Scott D. Ramsey. Universal Viral Screening of Patients with Newly Diagnosed Cancer in the United States: A Cost-efficiency Evaluation. Cancer Research Communications 2023; 3(9) doi: 10.1158/2767-9764.CRC-23-0255
|
| 17 |
Funda PEPEDİL TANRİKULU, Didar YANARDAĞ AÇIK, Bilal AYGUN, Mehmet BANKİR, Mikail ÖZDEMİR. The compliance of our practice of hepatitis B virus screening with the current guidelines in patients undergoing chemotherapy for hematological malignancies. Journal of Surgery and Medicine 2021; 5(11) doi: 10.28982/josam.981625
|
| 18 |
Priyanka Vashisht, James O’dell. Not all TNF inhibitors in rheumatoid arthritis are created equal: important clinical differences. Expert Opinion on Biological Therapy 2017; 17(8) doi: 10.1080/14712598.2017.1340453
|
| 19 |
Gretchen L. Bentz, Angela J. Lowrey, Dustin C. Horne, Vy Nguyen, Austin R. Satterfield, Tabithia D. Ross, Abigail E. Harrod, Olga N. Uchakina, Robert J. McKallip, Luwen Zhang. Using glycyrrhizic acid to target sumoylation processes during Epstein-Barr virus latency. PLOS ONE 2019; 14(5) doi: 10.1371/journal.pone.0217578
|
| 20 |
Romina Salpini, Arianna Battisti, Luna Colagrossi, Domenico Di Carlo, Lavinia Fabeni, Lorenzo Piermatteo, Carlotta Cerva, Miriam Lichtner, Claudio Mastroianni, Massimo Marignani, Sarah Maylin, Constance Delaugerre, Filomena Morisco, Nicola Coppola, Aldo Marrone, Mario Angelico, Loredana Sarmati, Massimo Andreoni, Carlo‐Federico Perno, Francesca Ceccherini‐Silberstein, Valentina Svicher. A snapshot of virological presentation and outcome of immunosuppression‐driven HBV reactivation from real clinical practice: Evidence of a relevant risk of death and evolution from silent to chronic infection. Journal of Viral Hepatitis 2019; 26(7) doi: 10.1111/jvh.13101
|
| 21 |
Ryo Yamauchi, Yasuaki Takeyama, Kazuhide Takata, Atsushi Fukunaga, Kunitoshi Sakurai, Takashi Tanaka, Hiromi Fukuda, Sho Fukuda, Hideo Kunimoto, Kaoru Umeda, Daisuke Morihara, Keiji Yokoyama, Makoto Irie, Satoshi Shakado, Shotaro Sakisaka, Fumihito Hirai. Hepatitis B Virus Reactivation after Receiving Cancer Chemotherapy under Administration of Leuprorelin Acetate. Internal Medicine 2020; 59(9) doi: 10.2169/internalmedicine.3805-19
|
| 22 |
Alessandro Federico, Giuseppina Brancaccio, Marcello Dallio, Patrizia Iodice, Alessio Fabozzi, Salvatore Del Prete, Fortunato Ciardiello, Carmela Loguercio, Giovanni Battista Gaeta. Reactivation of hepatitis B virus in cancer patients treated with chemotherapy for solid tumors. Is the prophylaxis really required?. Digestive and Liver Disease 2017; 49(2) doi: 10.1016/j.dld.2016.11.004
|
| 23 |
Ilaria Lenci, Martina Milana, Giuseppe Grassi, Tommaso M Manzia, Carlo Gazia, Giuseppe Tisone, Roberta Angelico, Leonardo Baiocchi. Hepatitis B virus recurrence after liver transplantation: An old tale or a clear and present danger?. World Journal of Gastroenterology 2020; 26(18): 2166-2176 doi: 10.3748/wjg.v26.i18.2166
|
| 24 |
Weiwei Tang, Ziyi Chen, Wenling Zhang, Ye Cheng, Betty Zhang, Fan Wu, Qian Wang, Shouju Wang, Dawei Rong, F. P. Reiter, E. N. De Toni, Xuehao Wang. The mechanisms of sorafenib resistance in hepatocellular carcinoma: theoretical basis and therapeutic aspects. Signal Transduction and Targeted Therapy 2020; 5(1) doi: 10.1038/s41392-020-0187-x
|
| 25 |
Ju-Tao Guo, Haitao Guo. Metabolism and function of hepatitis B virus cccDNA: Implications for the development of cccDNA-targeting antiviral therapeutics. Antiviral Research 2015; 122 doi: 10.1016/j.antiviral.2015.08.005
|
| 26 |
Yen Loo Lim, Gerome Bohelay, Sho Hanakawa, Philippe Musette, Baptiste Janela. Autoimmune Pemphigus: Latest Advances and Emerging Therapies. Frontiers in Molecular Biosciences 2022; 8 doi: 10.3389/fmolb.2021.808536
|
| 27 |
María Buti, María L. Manzano, Rosa M. Morillas, Montserrat García-Retortillo, Leticia Martín, Martín Prieto, María L. Gutiérrez, Emilio Suárez, Mariano Gómez Rubio, Javier López, Pilar Castillo, Manuel Rodríguez, José M. Zozaya, Miguel A. Simón, Luis E. Morano, José L. Calleja, María Yébenes, Rafael Esteban, Vincent Wong. Randomized prospective study evaluating tenofovir disoproxil fumarate prophylaxis against hepatitis B virus reactivation in anti-HBc-positive patients with rituximab-based regimens to treat hematologic malignancies: The Preblin study. PLOS ONE 2017; 12(9) doi: 10.1371/journal.pone.0184550
|
| 28 |
Narmeen Rana, Bushra Munir, Nazeer Hussain, Nazia Imtiaz, Asif Gondal, Fahed Parvaiz. Seroprevalence, Biochemical Investigation and Risk Factor Assessment for HBV & HCV Infection in Hospital Based Patients of Islamabad, Pakistan. Journal of Bioresource Management 2020; 7(2) doi: 10.35691/JBM.0202.0127
|
| 29 |
Chunyan Yuan, Jing Peng, Renxiang Xia, Jian He, Tianji Qiu, Yunqing Yao. Reactivation of Occult Hepatitis B Virus Infection During Long-Term Entecavir Antiviral Therapy. Frontiers in Microbiology 2022; 13 doi: 10.3389/fmicb.2022.865124
|
| 30 |
Gérôme Bohelay, Frédéric Caux, Philippe Musette. Clinical and Biological Activity of Rituximab in the Treatment of Pemphigus. Immunotherapy 2021; 13(1) doi: 10.2217/imt-2020-0189
|
| 31 |
Deborah Rund. Prophylaxis for hepatitis B reactivation during and after chemotherapy: many questions, some answers. Leukemia & Lymphoma 2016; 57(6) doi: 10.3109/10428194.2015.1131279
|
| 32 |
Z. Liu, L. Jiang, G. Liang, E. Song, W. Jiang, Y. Zheng, C. Gong. Hepatitis B virus reactivation in breast cancer patients undergoing chemotherapy: A review and meta‐analysis of prophylaxis management. Journal of Viral Hepatitis 2017; 24(7) doi: 10.1111/jvh.12672
|
| 33 |
Igor Snast, Lihi Atzmony, Marius Braun, Emmilia Hodak, Lev Pavlovsky. Risk for hepatitis B and C virus reactivation in patients with psoriasis on biologic therapies: A retrospective cohort study and systematic review of the literature. Journal of the American Academy of Dermatology 2017; 77(1) doi: 10.1016/j.jaad.2017.01.037
|
| 34 |
Serdar DURAK, Arif Mansur COŞAR. Evaluation of the safety and antiviral efficacy of the tenofovir alafenamide fumarate molecule in immunosuppressed patients. Journal of Health Sciences and Medicine 2022; 5(6) doi: 10.32322/jhsm.1179106
|
| 35 |
Ka-Shing Cheung, Wai-Kay Seto, Ching-Lung Lai, Man-Fung Yuen. Prevention and management of hepatitis B virus reactivation in cancer patients. Hepatology International 2016; 10(3) doi: 10.1007/s12072-015-9692-3
|
| 36 |
Stijn J De Keukeleire, Tijl Vermassen, Zahra M Nezhad, Tessa Kerre, Vibeke Kruse, Hans Van Vlierberghe, Karim Vermaelen, Sylvie Rottey. Managing Viral Hepatitis in Cancer Patients Under Immune Checkpoint Inhibitors: Should we Take the Risk?. Immunotherapy 2021; 13(5) doi: 10.2217/imt-2020-0273
|
| 37 |
Brian McMahon, Joan Block, Timothy Block, Chari Cohen, Alison A. Evans, Anu Hosangadi, W. Thomas London, Morris Sherman. Hepatitis-Associated Liver Cancer: Gaps and Opportunities to Improve Care: Table 1.. Journal of the National Cancer Institute 2016; 108(4) doi: 10.1093/jnci/djv359
|
| 38 |
Faisal Inayat, Fei Song, Nouman Safdar Ali, Muhammad Haseeb Aslam, Aishatu Aloma, Hilal Hachem, Muhammad Wasif Saif. Hepatitis B virus reactivation following imatinib therapy: A comparative review of 9 cases. Journal of Oncology Pharmacy Practice 2019; 25(6) doi: 10.1177/1078155218790337
|
| 39 |
Jiang Chen, Renan Jin, Jie Zhao, Jinghua Liu, Hanning Ying, Han Yan, Senjun Zhou, Yuelong Liang, Diyu Huang, Xiao Liang, Hong Yu, Hui Lin, Xiujun Cai. Potential molecular, cellular and microenvironmental mechanism of sorafenib resistance in hepatocellular carcinoma. Cancer Letters 2015; 367(1) doi: 10.1016/j.canlet.2015.06.019
|
| 40 |
Nobuhiko Nakamura, Hisashi Tsurumi, Masahito Shimizu. The Liver in Systemic Diseases. 2016; doi: 10.1007/978-4-431-55790-6_14
|